Is Amylyx Pharmaceuticals Inc (AMLX) overvalued? · $561.6M cap
Amylyx Pharmaceuticals Inc (AMLX) is a biotechnology company listed on US.
This page asks whether Amylyx Pharmaceuticals Inc (AMLX) looks expensive on cached numbers — not a short thesis.
Latest reported AMLX revenue for 2025-12-31 was $0. Net income was -$144.7M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AMLX currently screens at market cap $561.6M.
AMLX currently screens at market cap $561.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AMLX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AMLX stock page for the full model, not this heading.
Not investment advice.